Innoviva Inc.
951 Gateway Boulevard
South San Francisco
California
94080
United States
Tel: 650-808-6000
Website: http://www.thrxinc.com/
452 articles about Innoviva Inc.
-
Innoviva Names Pavel Raifeld as Chief Executive Officer
5/21/2020
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”) today announced the appointment of Pavel Raifeld as Chief Executive Officer effective May 20, 2020. Mr. Raifeld is a seasoned healthcare executive with a strong background in strategy, business development and corporate finance and has focused much of
-
Innoviva Reports First Quarter 2020 Financial Results
4/29/2020
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva," or "the Company") today reported financial results for the first quarter ended March 31, 2020.
-
Innoviva Announces Change of Location of Annual Meeting of Stockholders to Be Held on April 24, 2020
3/31/2020
Innoviva, Inc. announced that, due to the public health impact of the coronavirus pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in a virtual meeting format only.
-
Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.
3/30/2020
Funds to be used primarily to advance its lead Pseudomonas aeruginosa candidate, AP-PA02
-
Innoviva Reports Fourth Quarter 2019 Financial Results
2/5/2020
Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2019.
-
Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs
1/28/2020
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), and Innoviva, Inc. (NASDAQ: INVA) ("Innoviva"), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, today announced that they have entered into a securities purchase agreement pursuant to which Innoviva will purchase,
-
Innoviva Reports Third Quarter 2019 Financial Results
10/30/2019
Innoviva, Inc. (NASDAQ: INVA) (the “Company”) today reported financial results for the third quarter ended September 30, 2019.
-
GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma
10/2/2019
GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI), for the treatment of asthma in adults.
-
Innoviva Reports Second Quarter 2019 Financial Results
7/24/2019
Innoviva, Inc. (NASDAQ:INVA) (the Company) today reported financial results for the second quarter ended June 30, 2019.
-
Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint
5/2/2019
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol: FF/UMEC/VI) compared to Relvar/Breo Ellipta (FF/VI), in the treatment of patients living with uncontrolled asthma.
-
Innoviva Reports Fourth Quarter 2018 Financial Results
2/6/2019
Innoviva, Inc. reported financial results for the fourth quarter ended December 31, 2018.
-
Innoviva Reports Third Quarter 2018 Financial Results
10/31/2018
Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the third quarter ended September 30, 2018.
-
Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe
9/21/2018
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta
-
Innoviva Reports Second Quarter 2018 Financial Results
7/26/2018
Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017.
-
GSK Submits Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD
5/29/2018
GlaxoSmithKline plc and Innoviva Inc., today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for once-daily fluticasone furoate/umeclidinium/vilanterol under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease (COPD).
-
Innoviva Reports First Quarter 2018 Financial Results
4/26/2018
Royalties earned rose 28% to $55.8 million compared with the first quarter of 2017.
-
Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD
4/18/2018
GlaxoSmithKline plc and Innoviva, Inc. announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, one of the biggest ever conducted in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbation.
-
GSK Announces Positive EU Approval for Labelling Update to Relvar Ellipta in Patients with Asthma
3/8/2018
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
-
Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results
2/9/2018
Income from operations for the fourth quarter of 2017 was $66.4 million, compared with $37.7 million for the same period in 2016.
-
Innoviva to Report Fourth Quarter Financial Results on February 8 at 5:00 p.m. EDT
2/5/2018
Innoviva announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017.